Conclusions: Integrating 68Ga-PSMA-11 imaging biomarkers with clinical parameters, such as CAPRA, significantly improves models to predict progression in patients with high-risk PCa undergoing primary treatment. Here, FOLH1 is linked to posterior cortical atrophy.